A Theoretical View of Ovarian Cancer Relapse

Ovarian cancer (OC) is a disease that almost invariably relapses even after optimal primary cytoreductive surgery and standard first-line platinum-based chemotherapy. After recurrence, progressions occur at shorter intervals in the natural history of the disease. However, the biologic and cellular e...

Full description

Bibliographic Details
Main Authors: Gonzalo H. Giornelli, Pablo Mandó
Format: Article
Language:English
Published: European Medical Journal 2017-08-01
Series:European Medical Journal
Subjects:
Online Access:https://www.emjreviews.com/oncology/article/a-theoretical-view-of-ovarian-cancer-relapse/
_version_ 1819085989367250944
author Gonzalo H. Giornelli
Pablo Mandó
author_facet Gonzalo H. Giornelli
Pablo Mandó
author_sort Gonzalo H. Giornelli
collection DOAJ
description Ovarian cancer (OC) is a disease that almost invariably relapses even after optimal primary cytoreductive surgery and standard first-line platinum-based chemotherapy. After recurrence, progressions occur at shorter intervals in the natural history of the disease. However, the biologic and cellular events underlying recurrence and progression (maintenance phase) are yet to be completely understood. Ovarian adenocarcinoma, like any other tissue, after reduction of the cell population (cytoreduction) either by surgery, chemotherapy, radiotherapy, or targeted therapies induced cell-death, tends to its own renewal through cancer stem cells (CSC). CSC remain quiescent most of their lives and then ‘wake up’, generating a proliferative progeny that differentiates as they become different clones of daughter cells. What defines them is their ‘self-renewal’ potential, thus perpetuating the disease with higher tumour volume relapses in which CSC increase in number. We propose a theory of how recurrence/relapse occurs in which CSC play a key role in the genesis of relapse. These self-renewing CSC can generate a proliferative progeny and this population is sensitive to chemotherapy, anti-angiogenic agents, and PARP inhibitors, which so far have only increased the disease/relapse free survival (‘maintenance phase’). In OC it seems we are not addressing the ‘root’ of recurrence/relapse. As with any theory, this is based on both proven facts and suggested hypotheses, which may serve as investigation drivers towards finally making a substantial improvement in OC management.
first_indexed 2024-12-21T21:13:07Z
format Article
id doaj.art-e1949d3f9e924c8198f50e501f861695
institution Directory Open Access Journal
issn 2397-6764
language English
last_indexed 2024-12-21T21:13:07Z
publishDate 2017-08-01
publisher European Medical Journal
record_format Article
series European Medical Journal
spelling doaj.art-e1949d3f9e924c8198f50e501f8616952022-12-21T18:50:06ZengEuropean Medical JournalEuropean Medical Journal2397-67642017-08-0123128135A Theoretical View of Ovarian Cancer RelapseGonzalo H. Giornelli0Pablo Mandó1Genito Urinary Oncology Department, Instituto Alexander Fleming, Buenos Aires, ArgentinaGenito Urinary Oncology Department, Instituto Alexander Fleming, Buenos Aires, ArgentinaOvarian cancer (OC) is a disease that almost invariably relapses even after optimal primary cytoreductive surgery and standard first-line platinum-based chemotherapy. After recurrence, progressions occur at shorter intervals in the natural history of the disease. However, the biologic and cellular events underlying recurrence and progression (maintenance phase) are yet to be completely understood. Ovarian adenocarcinoma, like any other tissue, after reduction of the cell population (cytoreduction) either by surgery, chemotherapy, radiotherapy, or targeted therapies induced cell-death, tends to its own renewal through cancer stem cells (CSC). CSC remain quiescent most of their lives and then ‘wake up’, generating a proliferative progeny that differentiates as they become different clones of daughter cells. What defines them is their ‘self-renewal’ potential, thus perpetuating the disease with higher tumour volume relapses in which CSC increase in number. We propose a theory of how recurrence/relapse occurs in which CSC play a key role in the genesis of relapse. These self-renewing CSC can generate a proliferative progeny and this population is sensitive to chemotherapy, anti-angiogenic agents, and PARP inhibitors, which so far have only increased the disease/relapse free survival (‘maintenance phase’). In OC it seems we are not addressing the ‘root’ of recurrence/relapse. As with any theory, this is based on both proven facts and suggested hypotheses, which may serve as investigation drivers towards finally making a substantial improvement in OC management.https://www.emjreviews.com/oncology/article/a-theoretical-view-of-ovarian-cancer-relapse/ovarian cancer (oc)relapsed ovarian cancercancer stem cells (csc)maintenance therapy
spellingShingle Gonzalo H. Giornelli
Pablo Mandó
A Theoretical View of Ovarian Cancer Relapse
European Medical Journal
ovarian cancer (oc)
relapsed ovarian cancer
cancer stem cells (csc)
maintenance therapy
title A Theoretical View of Ovarian Cancer Relapse
title_full A Theoretical View of Ovarian Cancer Relapse
title_fullStr A Theoretical View of Ovarian Cancer Relapse
title_full_unstemmed A Theoretical View of Ovarian Cancer Relapse
title_short A Theoretical View of Ovarian Cancer Relapse
title_sort theoretical view of ovarian cancer relapse
topic ovarian cancer (oc)
relapsed ovarian cancer
cancer stem cells (csc)
maintenance therapy
url https://www.emjreviews.com/oncology/article/a-theoretical-view-of-ovarian-cancer-relapse/
work_keys_str_mv AT gonzalohgiornelli atheoreticalviewofovariancancerrelapse
AT pablomando atheoreticalviewofovariancancerrelapse
AT gonzalohgiornelli theoreticalviewofovariancancerrelapse
AT pablomando theoreticalviewofovariancancerrelapse